Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

Resverlogix Announces TSX Review Update

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today it has received a 30-day extension to no later than May 14, 2018 for the TSX’s review of the Company’s compliance with all of the TSX listing requirements.

As previously reported, as a result of the Company’s reliance upon the financial hardship exemption in connection with the Company’s previously-announced $87 million private placement with Shenzhen Hepalink Pharmaceutical Co. Ltd., the TSX commenced an automatic remedial delisting review, which is normal practice when a listed issuer relies on this exemption. The Company anticipates further improving its financial position by raising additional capital, including closing a previously-announced US$30 million senior secured loan.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only chronic BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations

Email: ir@resverlogix.com

Phone: 403-254-9252

Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to  the Phase 3 BETonMACE clinical trial, Phase 2a kidney dialysis clinical trial and Fabry Disease clinical trial, the Company’s intention to raise additional capital, including a senior secured loan, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Add Comment

Your email address will not be published. Required fields are marked *

Do NOT follow this link or you will be banned from the site!